The live attenuated DGAT1-knockout whole-cell Toxoplasma vaccine confers protective immunity against acute and chronic toxoplasmosis
The study demonstrates that a live-attenuated *Toxoplasma gondii* vaccine strain lacking the DGAT1 enzyme is safe, induces robust mixed Th1/Th2 immunity, and confers complete, long-lasting protection against both acute type I and chronic type II toxoplasmosis in mice.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Toxoplasma gondii is a microscopic parasite that lives inside the cells of warm-blooded animals, including humans. It is one of the most common infections on Earth, with roughly one in three people carrying it silently in their bodies. While the parasite usually causes no symptoms in healthy people, it can be devastating for those with weakened immune systems or for a fetus if a pregnant woman becomes infected. The parasite survives by stealing nutrients from its host, particularly fatty acids, which it stores in tiny, oil-filled pockets called lipid droplets. These droplets act as a pantry, allowing the parasite to hoard energy and protect itself from the toxic effects of having too much fat floating around its cells. For decades, scientists have known that blocking the parasite's ability to make these storage pockets slows it down, but creating a safe vaccine has remained a difficult challenge because the parasite is so adept at hiding and changing.
A team of researchers at Johns Hopkins University and the US Food and Drug Administration has now developed a new approach by genetically altering the parasite to strip away its ability to store fat. They focused on a specific enzyme, a protein machine inside the parasite called DGAT1, which is responsible for packaging fatty acids into those protective lipid droplets. Using precise gene-editing tools, the scientists removed the gene that produces this enzyme from a highly dangerous strain of the parasite. Without this enzyme, the parasite cannot store its excess fat. Instead, the fat builds up inside the cell, becoming toxic and causing the parasite to grow very slowly, lose its shape, and eventually die. The researchers found that this weakened version of the parasite, which they created in the lab, is completely harmless to mice, even those with very weak immune systems. It does not make them sick, and it does not kill them, even when large numbers of the altered parasites are injected into their bodies.
The team then tested whether this harmless, fat-starved parasite could teach the immune system to fight off the real, dangerous version. They injected mice with the weakened strain and waited to see what happened. The mice did not get sick, but their immune systems woke up and learned to recognize the parasite. Over the next six months, the vaccinated mice produced high levels of protective antibodies and developed a strong army of memory cells, which are the immune system's long-term guards. When the researchers later challenged these vaccinated mice with a lethal dose of the wild, dangerous parasite, the vaccinated animals remained healthy. They did not lose weight, they did not get sick, and they survived. In contrast, mice that had not received the vaccine became critically ill and died within days. The protection was so strong that it worked against two different types of the parasite: the fast-growing type that causes acute illness, and the slow-growing type that forms cysts in the brain and muscles, which is the form that causes chronic, lifelong infection.
To understand exactly how this protection worked, the scientists removed specific parts of the immune system from the vaccinated mice to see which ones were essential. They found that the protection relied heavily on a specific signaling molecule called interferon-gamma, which acts as a general alarm for the immune system. They also discovered that a specific type of white blood cell, the CD8 T cell, was crucial for controlling the infection. Surprisingly, while these cells were vital, the mice did not need their CD4 T cells to survive the initial attack, suggesting that the vaccine triggers a very direct and efficient defense. However, the study did show that B cells, which are responsible for making antibodies, were necessary for the vaccine to work fully. Mice without B cells could survive a little longer than unvaccinated mice, but they could not stop the infection completely. This indicates that the vaccine works best when it can generate both a cellular army and a supply of antibodies.
The researchers also observed that the amount of the weakened parasite used for vaccination influenced the type of immune response the mice developed. A smaller dose tended to trigger a response focused on cellular defense, while a larger dose created a mix of cellular and antibody-based defenses. Regardless of the dose, the protection lasted for at least six months, and the immune system remained ready to fight off the parasite even after that time. The study confirms that the weakened parasite does not revert to a dangerous form, a major safety concern with previous live vaccines. Because the parasite cannot store fat, it is fundamentally broken and cannot survive long enough to cause disease or form the cysts that lead to chronic infection. This makes it a promising candidate for a vaccine that could protect both humans and farm animals from toxoplasmosis, potentially stopping the spread of the disease at its source and preventing the severe complications that arise from infection during pregnancy or in immunocompromised individuals.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.